Imiquimod 5% cream in the treatment of human papillomavirus-16-positive erythroplasia of Queyrat.

Abstract

Erythroplasia of Queyrat is a human-papillomavirus-associated carcinoma in situ of the penis. Imiquimod, a new topically applied immunomodulatory agent, has been successfully used in the treatment of anogenital warts. We report the complete clearance of HPV-16-positive erythroplasia of Queyrat with 5% imiquimod cream.

• Authors: Markus Kaspari, Ralf Gutzmer, Peter Kiehl, Pia Dumke, Alexander Kapp, Jens P Brodersen
• Journal: Dermatology (Basel, Switzerland) (Dermatology) Vol. 205 Issue 1 Pg. 67-9 ( 2002) ISSN: 1018-8665 [Print] Switzerland
• PMID: 12145439 (Publication Type: Case Reports, Journal Article)
• Copyright: Copyright 2002 S. Karger AG, Basel

Chemical References

• Adjuvants, Immunologic
• Aminoquinolines
• Antineoplastic Agents
• Imiquimod

Topics

• Adjuvants, Immunologic (administration & dosage)
• Administration, Topical
• Adult
• Aminoquinolines (administration & dosage)
• Antineoplastic Agents (administration & dosage)
• Carcinoma in Situ (drug therapy, pathology, virology)
• Erythroplasia (drug therapy, pathology, virology)
• Humans
• Imiquimod
• Male
• Papillomaviridae
• Papillomavirus Infections (complications, drug therapy, pathology)
• Penile Neoplasms (drug therapy, pathology, virology)
• Penis (pathology)
• Tumor Virus Infections (complications, drug therapy, pathology)